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Abstract
Background: Persistence of c-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA
double strand breaks in treated cells.
Methods: DU-145 prostate cancer cells were treated with a chemical library 6IR and assayed for persistence of c-H2AX
using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of c-
H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and
biochemical assays and in vivo activity was tested in a validated Drosophila cancer model.
Results: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of c-H2AX,
apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited
structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA
microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and
protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity.
Conclusions: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as
radiosensitizing compounds as inhibitors of ribonucleotide reductase.
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Introduction
Despite the central role of DNA damage repair in determining
efficacy of radiation therapy (RT) or cytotoxic chemotherapy,
developing specific inhibitors of DNA damage repair is a relatively
unexplored area of research [1]. In the pharmaceutical and
biotechnology industries, high throughput screening is a central
function in the drug discovery process [2]. To date, this strategy
has only recently been applied to experimental radiotherapy [3,4].
The most common high-throughput screens are biochemical
assays that screen for compounds that interact with an isolated
protein on an assay plate [2]. In contrast, a cell-based approach
provides insight into the permeability profile of active compounds
and enables the identification of compounds with unique
mechanisms of action [5]. Charged-coupled device (CCD)
camera- based plate imaging systems allow for high throughput
quantitation of cellular and subcellular fluorescence in whole cells
[6]. These high content cell based assays allow for screening
compounds that impact cellular functions, such as cell cycle, cell
motility, apoptosis and DNA repair [6]. Current disadvantages of
this approach include limited throughput related to incompatibil-
ity of some steps of a complex screening procedure with full
automation, the relatively high cost of reagents and data-
management issues. Despite these technical hurdles, there is
significant interest in applying high content screening to primary
drug screening [5].
Exposure to IR and many chemotherapy agents, including
DNA synthesis inhibitors, DNA alkylators and topoisomerase I
inhibitors, result in DNA double strand breaks (DSB) [7,8,9]. A
single unrepaired DSB may result in cell death demonstrating the
critically important role of DNA damage repair in maintaining
genomic integrity [10]. An emerging concept is that the
physiological target of IR is not DNA alone but rather DNA in
the three-dimensional context of chromatin within a complex and
highly regulated protein-DNA structure [11]. ATM and related
kinases phosphorylate Serine 139 on H2AX to form foci of c-
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by light microscopy [12,13]. The phosphorylation of H2AX at
DSBs has been implicated in the timely recruitment and/or
retention of DNA repair and checkpoint proteins such BRCA1,
MRE11/RAD50/Nbs1 complex, MDC1 and 53 bp1 to sites of
DNA damage [9,14,15,16]. Downstream signal transduction
pathways may result in DNA damage repair (homologous
recombination, non-homologous end joining), cell cycle arrest or
apoptosis [17]. c-H2AX interacts with NuA4, INO80 and SWRC,
proteins that play a key role in chromatin remodeling and histone
acetylation. The cohesion complex, which joins sister chromatin
allowing for efficient homologous recombination repair of DSB
appear to localize to sites of DSB via interaction with the INO80
complex [18,19]. Persistence of c-H2AX between 3 to 24 hours
following experimental treatment is strongly associated with
unrepaired DNA DSB and sensitivity to DNA damaging therapies
[20]. Based on these data, we performed a proof-of-concept screen
to identify agents that increased persistence of c-H2AX at 4 hours
after drug treatment and ionizing radiation by inhibiting DNA
damage repair. Using a reverse chemical genetics approach, a
secondary focus of this study is to elucidate the molecular target of
lead compounds identified by the screen [6].
Results
High-content Screening for Compounds that Effectively
Induce c-H2AX and Reduce Tumor Cell Viability
We screened 14,400 compounds in 480 mixtures of 30
compounds for the specific phenotype of increased c-H2AX in
DU-145 prostate cancer cells at 4 hours after drug therapy alone
or in combination with 2 Gy of radiation. We identified 2
compound mixtures that had an especially strong effect on
inducing c-H2AX foci at a dose of 10 mM for 4 hours with or
without radiation (Figure 1a). An additional 12 compound
mixtures demonstrated a weaker positive effect. Only the 2
compound mixtures that significantly induced c-H2AX reduce cell
viability, while the 12 compound mixtures that weakly induced c-
H2AX did not significantly affect cell viability.
To identify the specific active compounds from these two
mixtures, we then tested mixtures of 10 compounds derived from
the parent 30 compound mixtures for induction c-H2AX 4 hours
after treatment. Based on these results, we ultimately tested
individual compounds for increased persistence of c-H2AX and
decreased tumor cell viability. Through this unbiased screening
process, we identified the 2 most active small molecules as
MS0019266 (2-pyridinecarbaldehyde 2-pyridinylhydrazone; mo-
lecular weight 198.2) and MS0017509 (1-(2-pyridinyl) ethanone
(4,6-dimethyl-2-pyrimidinyl)hydrazone); molecular weight 241.3)
(Figure 1A). Both MS0019266 and MS0017509 significantly
inhibited DU-145 tumor cell viability at doses as low as 5 mM
(Figures 1B and C). Further studies demonstrated that SCC-25,
SCC-61 and SQ-20B head and neck cancer cells are sensitive to
MS0019266 at doses as low as 0.2 mM while PC-3 prostate cancer
cells as low as 5 mM (Figures S1 and S2).
MS0019266 Markedly Reduces DNA Synthesis, Induces
Apoptosis and Increases Persistence of c-H2AX in
Combination with Ionizing Radiation
Evaluation of the chemical structures of MS0019266 and
MS0017509 demonstrates shared structural motifs (Figure 1a).
Since MS0019266 is slightly more active than MS0017509
according to MTS data, we first characterized the effects of
MS0019266 on DU-145 cell biology. Based on cell cycle analysis,
treatment with MS0019266 (5 mM) resulted in a slight G1/S arrest
(Figure 1D). Assessment of BrdU incorporation confirmed a
significant reduction in DNA synthesis during S-phase in
MS0019266 treated cells (Figure 1E). Flow cytometric analysis
demonstrates significant induction of apoptosis in DU-145 cells at
doses $5 mM (Figure 2A and B). In combination with 4 Gy
ionizing radiation, MS0019266 markedly increases the induction
and persistence of c-H2AX foci at 6 to 24 hours after treatment
(Figure 2C).
In-vitro Radiosensitizing Effects of MS0019266 and
MS0017509
To determine the effects of MS0019266 and MS0017509 on
prostate cancer radiosensitivity, clonogenic assays were performed
on the DU-145 cell line. As shown in Fig.3A, pretreatment DU145
cells with1 mM MS0019266 and MS0017509 respectively, a dose
at which MS0019266 and MS0017509 did not cause any loss of
viability, induced significant radiosensitization compared to
vehicle control alone (p,0.05 at all dose levels). Corresponding
dose enhancement ratios (DER) was 2.3 and 2.1 respectively. This
effect was also confirmed in SQ20B head and neck cancer cells at
a sub-micromolar dose of MS0019266 (Figure S3).
Effect of MS0019266 on Genes Related to Cell Cycle, DNA
Repair and Apoptosis
Since the molecular targets of MS0019266 are unknown, we
performed comparative global gene expression analysis on DU-
145 cells at 8 hours after treatment with MS0019266 (5 mM)
(Figure 3B). MS0019266 resulted in the most significant reduction
in polo-like kinase (PLK-1; 2.7 fold reduction) gene expression
(Table 1). There was also evidence of a 1.8 to 2.4 fold reduction in
the expression of genes related to cell cycle regulation and mitosis
including kinesin family member 20a, cyclin B1 and aurora kinase
A and a 4-fold increase in GADD45A expression. Genes
significantly increased by MS0019266 appeared non-specifically
related to treatment-related cell stress including tumor necrosis
factor associated protein 3, endothelin 1, NUAK2 and lysyl
oxidase (4 to 8.6 fold increase).
MS0019266 and MS0017509 Affects Protein Levels
Related to DNA Damage Repair and Apoptosis
To validate phenotypic functional and gene expression data in
treated cells, we performed immunoblotting to assess effects on
protein levels. To assess the effects of MS0019266 and
MS0017509 (10 mM for 4 hours) on DNA damage repair, we
determined the kinetics of c-H2AX induction and accumulation in
DU-145 cells. Although evidence of c-H2AX induction occurs as
early as 30 minutes after treatment, significant accumulation of c-
H2AX occurs at 4 hours and continues through at least 24 hours
after drug treatment (Figure 3C). Concurrent administration of
ionizing radiation and MS0019266 markedly amplifies this effect
strongly implicating inhibition of DNA double strand break repair
is a potential mechanism of action (Figure 3D). Following 4 Gy
ionizing radiation alone, BRCA1 accumulates 6 to 24 hours of
ionizing radiation as c-H2AX foci are being cleared (Figures 2C
and 3D). The accumulation of BRCA1 at 6 and 24 hours following
ionizing radiation is abrogated by treatment with MS0019266
(Figure 3D). Taken together, these data suggest a robust that
MS0019266 interferes with DNA double strand break repair
following ionizing radiation. To confirm the effect of MS0019266
or MS0017509 on apoptosis, we determined the kinetics of cleaved
caspase-3 accumulation in DU-145 cell. Cleaved caspase-3
accumulates in treated cells starting 4 to 6 hours after treatment
with MS0019266 or MS0017509 (Figure 3C and Figure 3D).
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Expression
Gene expression data suggests that PLK-1 is a potential target of
MS0019266. Immunoblotting of MS0019266 and MS0017509
(10 mM for 4 hours) demonstrates a potent reduction in PLK-1
protein levels at 24 hours after treatment, with or without ionizing
radiation (Figures 3C and D).
MS0019266 and MS0017509 Inhibit Ribonucleotide
Reductase Activity
Based on SciFinder search, chemical structures similar to
MS0019266 and MS0017509, such as 3-AP (triapine) have been
reported to inhibit ribonucleotide reductase (Figure S4) [21,22].
MS0019266 has no detectable effects on ribonucleotide reductase
M1 and ribonucleotide reductase M2 protein or gene expression
(data not shown). However, DU-145 cells treated with
Figure 1. Identification of MS0019266 and MS 0017509 as inhibitors of DNA damage repair. A) DU-145 prostate cancer cells were treated
with mixtures of 30 compounds from the 14,400 compound chemical library (10 mM) for 4 hours and stained for c-H2AX and then imaged with a
fluorescence microscope. MS0019266 (10 mM) and MS0017509 (10 mM) were identified as individual compounds that significantly increased c-H2AX
within 4 hours of treatment. Hydroxyurea (200 mM) for 4 hours was used as a positive control. B and C) Both MS0019266 (10 mM) and MS0017509
(10 mM) treated DU-145 cells were assessed for cell viability using MTS assay. After 72 hours of treatment with MS0019266 and MS0017509
respectively resulted in a significant decrease of cell viability in a dose-dependent compared to vehicle controls. Results are reported as means 6SEM
and normalized to control (*P,0.05, **P,0.01; vs. control as determined by two-tailed Student’s t-test). D) Cell cycle analysis by flow cytometry
demonstrated cells arrest in G1 phase at 24 hours after MS0019266 (5 mM) treatment. E) Cell proliferation was assessed by BrdU incorporation assay.
After 24 hours of treatment, DU145 cells were incubated with BrdU solution at final concentration of 10 mM for 30 min. MS0019266 (5 mM) markedly
reduced BrdU incorporation consistent with a marked decrease in DNA synthesis.
doi:10.1371/journal.pone.0038465.g001
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(200 mM) for 6 hours were all highly effective at inhibiting in vitro
ribonucelotide reductase activity compared to controls (Figure 3E).
Both MS0019266 (10 mM) and MS0017509 (10 mM) were at least
as effective as hydroxyurea (200 mM).
MS0019266 Suppresses Tumorigenesis in a Drosophila
Model of MEN2
Using the GAL4-UAS system, oncogenic Ret isoforms can be
expressed simultaneously in various tissues of the developing
Drosophila larvae (ptc. dRet
MEN2B ). This leads to only ,55% of the
ptc. dRet
MEN2B embryos reaching pupal stages and none to
adulthood due to lethal progression of ret-mediated eye tumors.
Known ret inhibitors, like Sorafenib and ZD6474, can suppress
the dRet
MEN2B-induced rough eye phenotype and increase propor-
tion of animals reaching pupal and adult stages. When larvae
expressing oncogenic Ret (ptc. dRet
MEN2B ) were fed compound
MS0019266 (100 nM to 50 mM), there was a significant increase
in viability of these organisms, and resulted in a significantly
higher proportion reaching pupae (,70% to ,90%) and adult
stages (,25% to ,90%) compared to vehicle control (Figure 4a).
Development of pupae appeared to be dose dependent up to doses
of 10 mM. In contrast, development of adult Drosophila was not
dose dependent but was increased 7 fold compared to vehicle only
controls (Figure 4b). This suggests that compound MS0019266
can suppress oncogenic signaling in-vivo at doses not associated
with lethal toxicity. Treatment with 100 nM or 10 mMo f
MS0019266 was able to partially suppress the hyper-proliferative
capacity of dRet
MEN2B expressing cells, which were eliminated from
the adult eye in 5 to 10% of treated flies (Figure 4c).
Figure 2. Effect of MS0019266 on apoptosis and DNA damage repair. A and B) Effect of MS0019266 on apoptosis. Annexin V level after 72 h
of treatment with MS0019266 (ranging from 1–10 mM) in DU145 cells was examined by flow cytometry. MS0019266 significantly increased apoptosis
in DU145 cells at doses $5 mM. C) Effect of MS0019266 on induction of c-H2AX foci as measured by immunocytochemistry. Combined treatment
with MS0019266 (10 mM) and 4 Gy ionizing radiation significantly increases nuclear c-H2AX foci at 6 to 24 hours after treatment compared to
radiation alone.
doi:10.1371/journal.pone.0038465.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38465Figure 3. MS0019266 and MS0017509 enhance tumor cell radiosensitivity and specifically targets ribonucleotide reductase and
polo-like kinase 1. A) Colony formation assay performed on DU145 cells. Pretreatment with MS0019266 and MS0017509 (1 mM for 72 hours)
significantly reduced clonogenic survival in DU-145 prostate cancer cells subsequently treated with ionizing radiation administered 24 hours after
drug administration. Following 72 hours of drug treatment, cells were switched to drug free media. Results are the average of experiment and each
experiment was done in triplicate (n=3). * denotes p,0.05 and ** denotes p,0.01 vs. vehicle control. B) Gene expression changes following
treatment with MS0019266 as assessed by gene expression microarray. Genes showing differential expression between MS0019266 (5 mM for 8
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Approximately 1 in 4 deaths in the United States are caused by
cancer that is refractory to therapy, suggesting that further
improvements in anticancer therapy are urgently needed [23,24].
One approach to overcoming radiation resistance is utilizing
combined chemotherapy and radiation, which improves survival
compared to RT alone in locally advanced brain, cervix, lung,
head and neck, rectal, esophagus, bladder and anal cancers [25].
The rationale for using cytotoxic chemotherapy as a radiosensi-
tizer is based on the rationale that additional DNA damage may
lower the threshold of cell death by ionizing radiation (IR).
Although clinically significant radiosensitization has been achieved
with cytotoxic chemotherapy, this approach is limited by lack of
tumor cell selectivity, resulting in increased toxicity [24].
To address the unmet need for developing new treatments to
further improve cancer treatment, such as small molecule
inhibitors, new and innovative approaches are needed. Despite
the central role of DNA damage repair in determining response to
radiation, therapies that inhibit this process have not been
successfully developed as clinically useful radiosensitizers [1]. For
instance, wortmannin, caffeine or LY294002 have not been
clinically useful radiosensitizers due to lack of tumor cell specificity
resulting in an unacceptable toxicity profiles [26]. Recently PARP
inhibitors have been shown to be highly effective in tumors with an
underlying susceptibility to DNA damage, such as BRCA1 and
BRCA2 mutation related cancers [27]. Further progress in this
area was limited by a lack of a practical biological reporter of
abrogated DNA damage repair for drug development programs.
H2AX phosphorylation as performed by either flow cytometry or
96-well immunocytochemistry allows the investigator to efficiently
determine the effects of RT and drug therapy on DNA damage
repair [28].
In this report, we describe a high-content approach to
identifying novel inducers and/or inhibitors of DNA damage
repair with radiosensitizing activity by performing high content
screening of increased c-H2AX after radiation. Analysis of the
chemical structures of the two compounds that were positive on
both primary and secondary screening assays showed significant
structural similarity. Based on structural similarity to tripine, we
hypothesized that these agents were ribonucleotide reductase
inhibitors [29]. One prior report demonstrated that substituted
20acylpyridine-a-(N)-Hetarylhydrazones related to MS0019266
and MS0017509 inhibit ribonucleotide reductase in Ehrlich tumor
cells and mouse leukemia L1210 cell growth in culture [29]. In this
report, we demonstrated that both MS0019266 and MS0017509
have physiologically significant effects on DNA damage repair, cell
cycle arrest, tumor cell proliferation and apoptosis. Although we
hypothesize that the radiosensitizing effects of MS0019266 and
MS0017509 is due to inhibition of ribonucleotide reductase
resulting in impaired DNA double strand break repair, an indirect
effect related to redistribution of cells within the cell cycle cannot
be ruled out.
Since MS0019266 was slightly more effective at inducing
apoptosis and cytotoxicity in prostate cancer cells than
MS0017509, we further investigated its effect on gene expression.
We demonstrated no effect of MS0019266 on ribonucleotide
reductase gene expression. This is consistent with prior studies
hours) treated cells and vehicle treated controls. Upregulated genes are shown in red and downregulated genes are shown in green. C) c-H2AX
cleaved, caspase3 and PLK1 expression were examined by immunoblotting. Administration of MS0019266 (10 mM) and MS0017509 (10 mM) for 4
hours resulted in significant accumulation of c-H2AX and cleaved caspase3 over time in DU-145 cells. In contrast, PLK1 is markedly decreased at 24
hours after drug treatment. D) Combined treatment with MS0019266 (10 mM for 4 hours) and ionizing radiation resulted in more significant
accumulation of c-H2AX compared to either MS0019266 or radiation alone. PLK1 is also markedly decreased at 24 hours after combined treatment
with radiation and MS0019266. Further, treatment of irradiated cells with MS0019266 (10 mM for 4 hours) markedly reduced the accumulation of
radiation-induced BRCA1 repair protein at 6 and 24 hours following ionizing radiation. E) MS0017509 and MS0019266 are potent inhibitors of in vitro
ribonucleotide reductase activity. Administration of MS0019266 (10 mM) and MS0017509 (10 mM) for 6 hours prior to CDP assay resulted in a similar
reduction of ribonucleotide reductase activity as hydroxyurea (200 mM) in treated DU-145 cells.
doi:10.1371/journal.pone.0038465.g003
Table 1. Genes Differentially Expressed in MS0019266-treated vs. vehicle control treated DU-145 cells.
Gene description Fold change Gene symbol
Upregulated ($4 fold increase)
Tumor necrosis factor, alpha-induced protein 3 8.6 TNFAIP3
Endothelin 1 6.8 EDN1
NUAK family, SNF1-like kinase, 2 6.1 NUAK2
Arrestin domain containing 4 4.7 ARRDC4
Growth arrest and DNA-damage-inducible, alpha 4.0 GADD45A
Lysyl oxidase 4.0 LOX
GTP binding protein overexpressed in skeletal muscle 4.0 GEM
Downregulated ($2 fold decrease)
Polo-like kinase 1 2.7 PLK1
Kinesin family member 20A 2.4 KIF20A
Family with sequence similarity 102, member B 2.2 FAM102B
Cyclin B1 2.1 CCNB1
Histone cluster 1, H1b 2.1 HIST1H1B
Exophilin 5 2.0 EXPH5
doi:10.1371/journal.pone.0038465.t001
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triapine, inhibit ribonucleotide reductase by generating reactive
oxygen species [30]. However, in addition to reducing ribonu-
cleotide reductase activity, MS0019266 significantly reduced
expression of several genes related to cell cycle arrest and mitosis,
including polo-like kinase 1, kinesin family member 20a, cyclin
B1 and aurora kinase A. Treatment with either MS0019266 or
MS0017509 dramatically reduced polo-like kinase-1 protein
levels. It is not currently known whether MS0019266 or
MS0017509 are direct inhibitors of polo-like kinase 1 or whether
these compounds are non-specific inhibitors of mitotic proteins
through effects on cell cycle. Polo-like kinase-1 plays a key role in
cell cycle, including centrosome maturation and G2/M transi-
tion, and is a promising antitumor target [31]. Recent preclinical
data suggests that polo-like kinase-1 inhibitors have radiosensi-
tizing activity [32]. Search of the Ingenuity Pathways Analysis
database demonstrates no known direct link between ribonucle-
otide reducase and polo-like kinase-1 (accessed July 17, 2010).
The in-vitro data were validated in two whole organism systems
to assess in vivo antitumor efficacy and toxicity. The Drosophila
model of MEN2 has been successfully used to study candidate
compounds to treat MEN2B, including ret inhibitor ZD6474.
Although there is no evidence that MS0019266 is a specific
inhibitor of ret, we used the Drosophila model as a novel
therapeutic discovery tool to demonstrate antitumor activity at
doses without whole organism toxicity. Further mammalian data
demonstrates no evidence of lethal systemic toxicity at doses that
were active in vitro and in Drosophila (unpublished data). Taken
together, MS0019266 and related compounds are promising anti-
tumor and radiosensitizing compound that is a candidate for
further development.
This study provides evidence that high-content screening as a
feasible approach to developing agents that inhibit DNA damage
repair. In this screen, we identified 2 compounds that are effective
ribonucleotide reductase inhibitors, a well validated biological
target for radiosensitization. Based on this preliminary experience,
screening a larger chemical library may identify additional agents
Figure 4. Results of MS0019266 administration in a Drosophila model of MEN2. A) MS0019266 treated fly embryos demonstrates a dose
dependent increase in survival to pupae stage in Drosophila suggesting antitumor efficacy. B) MS0019266 (0.1 to 50 mM) markedly increased
Drosophila surviving to adult stage suggesting that treated animals can tolerate doses into the micromolar range without lethal toxicity. C)
MS0019266 suppresses development of eye tumors related to RetMEN2B in vivo. Scanning electron micrographs of adult Drosophila eyes from flies
fed on control food (left panel) or food containing 100 nM MS0019266 (center and right panels). Large eye tumors developed in 100% of controls and
90% of MS0019266 treated flies. For 10% of flies fed MS0019266 during development, normal eye development was restored demonstrating effective
abrogation of RET-mediated tumor development.
doi:10.1371/journal.pone.0038465.g004
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high-throughput screening for radiosensitizers have been recently
described. Lally, et al performed a chemical library screen to
identify agents that decreased cell viability of U251 glioma cells
following radiation and drug therapy using a 96 well MTS assay
[3]. They identified NS-123, which appears to inhibit DNA
damage repair. Similarly, a 96-well colony forming assay was
developed with the goal of identifying radiosensitizers [33]. In
addition to providing information on DNA damage repair, this 96-
well c-H2AX assay could potentially be multiplexed for a high-
content readout [6]. Our protocol utilized pooling of compounds,
which is a commonly used approach to improve efficiency of
resource intensive high-content screening protocols [34]. However,
this strategy has the potential risks of additivity, synergy and
antagonism that could result in both false positives and false
negatives. We eliminated the risk of false positives through
subsequent interrogation of individual compounds. A further
disadvantage of pooled compound experiments is that the DMSO
concentration is higher to achieve adequate drug concentrations
and this is another potential confounding variable. To address the
risk of false negatives associated with pooling, we propose
subsequent screening of individual compounds from a larger
chemical library that can be justified by our success in this pilot
screen. In conclusion, MS0019266 and MS0017509 are promising
compounds that may be candidates for further development as
radiosensitizing compounds as inhibitors of ribonucleotide reduc-
tase and polo-like kinase 1.
Methods
Cell Lines and Cell Culture
We used one well characterized prostate cancer cell line
(DU145) for screening and biological analysis and confirmed
results in three human head and neck squamous carcinoma cancer
(HNSCC) cell lines (SQ-20B, SCC61, SCC-25) and one prostate
cancer cell line (PC-3) with known differences in radiosensitivity.
DU145 and PC-3 cells were purchased from ATCC and was
maintained in F-12K medium containing 10% fetal bovine serum
and 1% penicillin/streptomycin. HNSCC cell lines were kindly
provided by Dr. Aparna Ranganathan and maintained in
Dulbecco’s modified Eagle’s medium/F-12 supplemented with
20% fetal bovine serum, 0.4 mg/ml hydrocortisone, 4 mM L-
glutamine and 1% penicillin/streptomycin. Cells were maintained
at 37uC and 5% CO2.
Experimental Treatment
Cells were trypsinized from stock cultures, subcultured and
grown to 50–70% confluence in 96-well tissue-culture treated glass
bottom plates (Whatman Inc, Piscataway, NJ). Experimental
radiation was performed using a Varian 600c clinical linear
accelerator at a dose rate of 3.5 Gy/min and cells were
immediately returned to the cell incubator. For each screening
experiment, the chemical inhibitors were added to the media at
the desired concentration for 4 hours. The final DMSO
concentration were significantly less than 1% with single
compound experiments had DMSO concentrations less than
0.1%. Ionizing radiation (4 Gy) and hydroxyurea (200 mM for 4
hours) were used as positive controls.
Immunocytochemistry
We have previously described a 96-well immunocytochemistry
assay for c-H2AX [28]. Briefly, cells were treated with radiation
and fixed in 4% paraformaldehyde for 20 minutes after IR and/or
drug therapy permeabilized with 100% ice cold methanol for
3 hours. Subsequent PBS washes, blocking and staining steps were
performed on the Tecan Freedom Evo liquid handling robot.
Prior to primary antibody staining, cells were blocked using 3%
normal goat serum. Cells were incubated with anti-phospho-
H2AX polyclonal antibody (Cell Signaling, Danvers, MA) at
1:1000 dilution for 1 hour at room temperature, washed and
stained with Alexa 488 Fluor secondary antibody (Invitrogen,
Carlsbad, CA) at 1:600dilution for 60 minutes at room temper-
ature [20]. Washes were performed with PBS and nuclear staining
was performed using DAPI at 1 mg/mL. The wells are refilled with
PBS and cells were imaged under fluorescent microscope.
Semiautomated Microscopy and Analysis
The plates were imaged on an Olympus IX70 inverted confocal
microscope with a LUCPLAN x40/0.6 numerical objective
(Olympus, Center Valley, PA), Ludl focus motor, X-Y stage and
Uniblitz shutters. Image acquisition was performed with a cooled
Evolution QEi monochrome digital CCD camera (Media Cyber-
netics, Maryland, USA) operating at a maximum resolution of
139261040 pixels at 12 bits, with image transfer rate at 10 fps via
FireWire (IEEE 1393) digital interface. The software used to
visualize the images was InVitro Version 3.1.1 (Media Cybernet-
ics, Maryland, USA) on an Intel Pentium dual core processor with
a 30 inch wide screen monitor. After initial user intervention to
determine the approximate plane of the cells throughout the plate,
the automated software obtains images at two sites per well each
50 mm from the center of the well with 75 ms exposure time per
image. Each well was focused over a 6150 mm range, and each
site per well was focused over a 620 mm range. Each field contains
7 different focal planes in the z-dimension, with a step size of 1 mm
in between planes. Images were acquired under standardized
brightness and contrast settings.
Subsequently, images for each cell were visually screened using
ImageJ (National Institutes of Health, Bethesda, USA). Positives
were cells with significantly increased c-H2AX after treatment
compared to DMSO only control wells.
High-content Screening Design
The general algorithm for this preliminary screen is shown in
Fig. S5. Briefly, DU-145 cells were treated with control (DMSO
alone or hydroxyurea) or mixtures of 30 unknown compounds
from a commercially available 14,400 compound chemical library
(Chembridge, San Diego, CA) for 4 hours. This library was
chosen for its structural diversity and availability of compounds for
secondary assay and validation. Cells were stained for H2AX
phosphorylation as described above. To determine the specific
compound contributing to the phenotype observed in cells treated
by compound mixtures, we performed further analysis of mixtures
of 6 compounds followed by testing of individual compounds.
Cell Viability Assay
As the initial secondary screen, inhibitory effects of compounds
was evaluated by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS; Promega, Madison, WI) assay. Briefly, cells were seeded
in 96-well tissue culture plates at a density of 3610
3cells
per100 mL/well. Four wells were assigned to each experimental
treatment. After 24 hours for attachment, the compounds were
added in a range of concentrations as single agent (0–10 mM). After
72 hours of treatment, 10 mL of MTS solution was added to each
well for two hours incubation. Absorbance at 490 nm was recorded
using microplate reader.
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Clonogenic survival curves were determined as follows.
1610
3cells were plated in 6-well cell culture plate. Compounds
were added to cells 24 h later and irradiation was administered
24 h after drug treatment. Immediately after irradiation, the
cultures were returned to the incubator and drug treatment was
continued for a total of 72 hours. Subsequently, drug-containing
media was removed and replaced with drug-free media. Since
DU145 cells grow relatively slowly, cells were fixed and stained
with Giemsa at 14 days after treatment. In contrast, SQ20B cells
grow more rapidly and were ready for fixation and Giemsa
staining at 10 days. Only colonies of .50 cells were scored as
survivors. All data points are the results (mean 6 SD) of 3–4
experiments. To compare cell survival between groups, a two-
sample t test with unequal variances was utilized using Stata 8.0.
Immunoblotting Analysis
Treated cells were washed with cold PBS and lysed in lysis
buffer (Cell Signaling) using a standard protocol. The protein
concentration was analyzed by a protein assay kit with bovine
serum albumin standards according to the manufacturer’s
instructions (Bio-Rad Laboratories, Hurcules, CA). Cell lysate
was separated by SDS-PAGE and transferred onto a nitrocellulose
membrane (Hybond-C, Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ). Following blocking with PBS-Tween-20 contain-
ing 5% nonfat dry milk for 1 h, membranes were incubated
overnight at 4uC with anti–phospho-H2AX antibody, anti-cleaved
caspase 3 antibody, anti-RRM1 antibody, anti-RRM2 antibody,
anti-BRCA1 antibody and anti-PLK1 antibody followed by
incubation with horseradish peroxidase– conjugated secondary
antibody. b-actin was used as loading control. All antibodies for in
vitro experiments were purchased from Cell Signaling Technology
except RRM1 and RRM2 (Santa Cruz, Santa Cruz, CA).
Immunoreactive bands were detected by an enhanced chemilu-
minescence kit.
Annexin V Assay for Apoptosis
1610
5cells were plated in P25 flasks. Compound was added to
cells 24 hr later. At 72 h after treatment, cells were trypsinized and
washed with cold PBS. Flow cytometry analysis was performed
after cells were stained with both Annexin V and propidium iodine
(PI) for 15 minutes at room temperature.
Cell proliferation and cell cycle assay. For bromodeoxy-
uridine (BrdU) experiments, cells were incubated with BrdU at a
final concentration of 10 mM in cell culture medium after being
treated with compound at desired time point. Then cells were
fixed, permeabilized and stained with anti-BrdU antibody
according to a commercially available BrdU flow cytometry
staining protocol (BD Pharmingen, San Diego, CA). DNA content
was stained by incubation of the cells with 7-AAD solution. Cell
suspensions were analyzed with a BD FACSCalibur flow
cytometry. Data were analyzed with CellQuest software.
DNA Microarray
We performed GeneChip expression analysis to determine the
function of lead compounds. Total RNA was isolated with the
RNeasy Mini Kit (QIAGEN) from DU145 prostate cancer cells at
8 hours after drug treatment. RNA quality was assessed by agarose
gel electrophoresis demonstrating a 28S band that is 2 times more
intense than 18S ribosomal RNA. Synthesis of cDNA from total
RNA and hybridization/scanning of microarrays were performed
with Affymetrix GeneST1.0 array as described in the GeneChip
manual. The raw intensity data were extracted from the GeneChip
using Gene Expression Console (Affymetrix Inc.) and normalized
across the chips by log scale robust multi-array analysis (RMA)
method and the quality control of each chip data was performed by
investigating overall intensity values for all probes, negative and
positive controls [35]. To identify significantly differentially
expressed genes between groups such as treated vs. control
samples, Significance Analysis of Microarray (SAM, version2.1)
was carried out [36]. SAM is a widely-used microarray differential
analysis tool that correlates gene expression data to a wide variety
of clinical parameters and uses permutation to estimate False
Discovery Rate for multiple testing. The cutoff of FDR q value for
SAM test was set to 0.1. The gene expression data was also
integrated with Gene Ontology functional database using DAVID
to perform functional enrichment for better interpretation of gene
expression profiles in the context of biological function [37]. All
data is MIAME compliant and the raw data was deposited in
ArrayExpress (accession number E-MTAB-845).
Ribonucleotide Reductase Assay
RR activity was measured utilizing the CDP assay method as
previously described [30]. DU145 cells treated with MS0019266
(10 mM), MS0017509 (10 mM), hydroxyurea (200 mM) or vehicle
control were washed with cold PBS and detached by trypsin and a
cell scraper. Cells were transferred into a 15-mL tube and pelleted
by centrifugation at 300 g for 10 min at 4uC. The pellets were
washed again with PBS. One volume of low salt homogenization
buffer (10 mM of HEPES, pH 7.2, with 2 mM of DTT) was
added to the cell pellets. The cell suspension was homogenized by
Pyrex tissue grinder (20 times up and down on ice). After
homogenization, another 1x vol. of high salt buffer (1 M of
HEPES, pH 7.2, with 2 mM of DTT) was added. The cell
suspension was mixed by pipette (20 times up and down on ice).
Cell debris were removed by centrifugation at 16,000 g at 4u for
20 min. The supernatant was passed through a Sephadex G25
spin column, pre-equilibrated with buffer (50 mM of HEPES,
pH 7.2, 2 mM of DTT) to remove endogenous nucleotides.
Protein concentration was measured on NanoDrop ND-1000
spectrophotometer (OD 280). The reaction mixture in a final
volume of 50 ml contained the following: [
3H]CDP (0.5 mCi;),
HEPES (pH 7.2) (50 mM), DTT (6 mM), magnesium acetate
(4 mM), ATP (2 mM), CDP (0.05 mM), and a specific amount of
cell extract. The incubation time for the reaction was 20 min.
[
3H]dCDP was dephosphorylated by phosphodiesterase. [
3H]C
and [
3H]dC were separated with a C18 ion exchange column by
HPLC and detected by ß-RAM radioactive detector. The reaction
was linear during the process.
Multiple Endocrine Neoplasia Type 2 (MEN2) Whole
Organism Drosophila Model
To efficiently assess the whole organism toxicity and antitumor
activity of MS0019266, we used a well-established Drosophila
model of MEN2 [38]. Compound MS0019266 dissolved in
DMSO was mixed in melted fly food at ,55uC and 1 ml allowed
to set in a 5 ml plastic vial. 20–40 embryos of the indicated
genotype (ptc. dRet
MEN2B ) were transferred into each vial and
allowed to develop at 25uC. DMSO at maximal concentrations of
0.2% in fly food was used as control. Number of pupae and adults
were counted after ,2 weeks to establish viability percentage.
dRet
MEN2B mediated eye tumors were induced using the eyeless-
FLP MARCM system. Using this strategy, FLP-mediated mitotic
recombination initiated expression of oncogenic dRet
MEN2B in
small groups of cells mixed with wild type tissue. Clonal
propagation of the dRet
MEN2B expressing cells outcompeted
adjacent wildtype cells leading to adult eyes showing overgrowth
High Content Screening for Radiosensitizers
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38465phenotype. For the eyeless-FLP MARCM experiments,
y,w,eyFLP1; Act5C.y
+.Gal4, UAS-GFP; P[FRT]82B tub-Gal80
female virgins were crossed to P[FRT]82B UASdRet
MEN2B males
and their progeny raised in control or drug containing food.
Enclosed adults were frozen and eyes imaged using standard
scanning electron micrograph (SEM) procedures.
Supporting Information
Figure S1 MS0019266 treated SQ20B, SCC-61 and SCC-
25 cells were assessed for cell viability using MTS assay.
After 72 hours of treatment with MS0019266 (10 mM) resulted in
a significant decrease of cell viability in a dose-dependent
compared to vehicle controls. Results are reported as means
6SEM and normalized to control (*P,0.05, **P,0.01; vs. control
as determined by two-tailed Student’s t-test).
(TIF)
Figure S2 MS0019266 treated PC-3 cells were assessed
for cell viability using MTS assay. After 72 hours of
treatment with MS0019266 (10 mM) resulted in a significant
decrease of cell viability in a dose-dependent compared to vehicle
controls. Results are reported as means 6SEM and normalized to
control (*P,0.05, **P,0.01; vs. control as determined by two-
tailed Student’s t-test).
(TIF)
Figure S3 Colony formation assay performed on SQ20B
cells. MS0019266 (0.15 mM for 24 hours) significantly
reduced clonogenic survival in SQ20B head and neck
cancer cells subsequently treated with ionizing radia-
tion. Results are the average of experiment and each experiment
was done in triplicate (n=3).
(TIF)
Figure S4 Structural similarity between MS0019266 and
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
(3-AP, triapine).
(TIF)
Figure S5 Chemical library screening algorithm. Based
on extensive preliminary data, persistence of c-H2AX at 4 hours
after treatment with drug therapy was identified as a robust
phenotypic marker of unrepaired DNA damage and tumor cell
sensitivity. The c-H2AX immunocytochemistry assay has been
developed and validated on single glass coverslips. Subsequently,
an automated c-H2AX immunocytochemistry assay was devel-
oped using 96-well glass bottom plates and robotic liquid handling.
The initial chemical library screen was conducted with 30
compound mixtures from the 14,400 compound Chembridge
library. Images from 96-well plates were captured using a CCD
camera and analyzed off-line. The chemical compound resulting
in significant persistence of c-H2AX was identified using mixtures
of 6 compounds and subsequently single compounds. Highly
effective single compounds were assessed by MTT cell viability
and clonogenic assays as secondary screens.
(TIF)
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